With a 100% response rate in a Phase II study, KYV-101 sets a new efficacy bar in generalized myasthenia gravis, according to ...
Dr Katherine Ruzhansky previews presentations on biomarkers, new therapies, and translational science at AANEM 2025.
Data from the 52-week follow-up of the phase III MINT trial of inebilizumab (Uplizna) in generalized myasthenia gravis was ...
Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue," says Hesterlee. It occurs "when a person’s immune system is essentially attacking ...
Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia ...
MedPage Today on MSN
Myasthenia Gravis Complement Inhibitor Meets Primary Endpoint in Phase III Trial
SAN FRANCISCO -- Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor ...
MedPage Today on MSN
Myasthenia Gravis Drug Shows Benefits in Wider Range of Patients
Beyond the 4-week mark, both MG-ADL and Quantitative Myasthenia Gravis scores improved in the overall population and in all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback